History
First coronary angiography performed by
Mason Sones
In ACS, Prasugrel vs Plavix associated with reduced rates of ischemic events including stent thrombosis
TRITON-TIMI 38
Severe AS, GI bleeding, thrombocytopenia
Heyde's Syndrome
P2Y12 use in pt w/ TIA/CVA
Prasugrel
Used for refractory angina, MOA selective inhibitor of late Na sodium channel in myocardium
Ranolazine
First coronary balloon angioplasty
Andreas Gruentzig
Upstream pretreatment with prasugrel in NSTEMI patients did not reduce rate of MACE but increased major bleeding
Pulmonary stenosis with distinctive facial features
Noonan's Syndrome
Thrombolysis contraindicated in STEMI if ischemic stroke or significant closed head/facial trauma in the last ____
3 months
ATP citrate lyase inhibitor associated with lower risk of MACE
Bempedoic acid
First human heart transplant performed by
Christian Barnard
In ACS, ticagrelor as compared to clopidogrel reduced rate of death and MACE without increased rate of major bleeding but increase in rate of non-procedure related bleeding
PLATO
Lentiginosis, benign cardiac tumors
Carney Complex
Use of the off-label anti-hypertensive in the presence of pericardial effusion
Minoxidil
Van Gohh's "yellow period" might be attributed to an adverse effect from this medication
Digitalis/Digoxin
Discovered beta blocker and won the Nobelz prize
Sir James Black
In STEMI patients undergoing primary PCI, routine manual thrombectomy, as compared with PCI alone, did not reduce MACE within 180 days, but was associated with increased stroke within 30 days
Coarctation, subaortic stenosis, parachute mitral valve, supravalvular mitral ring
Shone Complex
Entire class of ____ are absolutely contraindicated in patients with an eGFR less than 30 mL
SGLT2 inhibitors
IMPROVE-IT trial found that adding this medication to moderate-high intensity statin decreased LDL further with modest decrease in coronary events in patients with prior ACS
Ezetimibe
This professor recorder the first ECG
Willem Einthoven
Early vs delayed invasive in UA/NSTEMI did not differ greatly in preventing MACE at 6 months, but early invasive strategy was superior in high risk patients
TIMACS
Autosomal dominant condition, congenital heart defects (most commonly ASD), bilateral upper extremity bone abnormality
Holt-Oram
This A2A agonist is considered contraindicated for patients with second-or third-degree AV block or sick sinus syndrome
Regadenoson
Oral soluble guanylate cyclase stimulator associated with decreased hospitalization for HF
Vericiguat